Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

INCLUSION CRITERIA

* Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
* AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60 years of age
* AML with multilineage dysplasia
* Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory disease, age 2 to 60 years
* ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease
* Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis
* Myelodysplastic syndrome (MDS), including World Health Organization (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS
* MDS with poor long-term survival including myeloid metaplasia and myelofibrosis
* Myeloproliferative disorders
* High-risk non-Hodgkin lymphoma (NHL) in 1st emission
* Relapsed or refractory NHL
* Hodgkin lymphoma (HL) beyond first remission
* Males and females of any ethnic background, 2 to 60 years of age
* Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status \> 70% for patients \< 16 years of age.
* Related, matched-donor identified \[6/6 human leukocyte antigen (HLA)-A, B and DRB1\]
* Willingness to take oral medications during the transplantation period
* Ability to understand and the willingness to sign a written informed consent document

EXCLUSION CRITERIA

* Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT)
* HIV infection
* Pregnant
* Lactating
* Evidence of uncontrolled active infection
* Serum creatinine \> 1.5 mg/dL or 24-hour creatinine clearance \< 50 mL/min
* Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 x upper limit of normal (ULN)
* Carbon monoxide diffusing capacity (DlCO) \< 60% predicted (adults) OR and in-room air oxygen saturation \< 92% (children)
* Left ventricular ejection fraction \< 45% (adults) OR shortening fraction \< 26%(children)
* Fasting cholesterol \> 300 mg/dL or Triglycerides \> 300 mg/dL while on lipid-lowering agents.
* Receiving investigational drugs unless cleared by the Principal Investigator (PI).
* Prior malignancies except basal cell carcinoma or treated carcinoma in-situ.
* Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer treated with curative intent \> 5 years will be allowed).